IO-INTERACTIVE
IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Veronique Lallier will be joining IOI as its new Chief Development Officer. Operating globally across all studios and situated in Brighton which opened in July 2023, Veronique will be charged with overseeing IOI’s game development strategy and production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116212318/en/
Veronique Lallier (Photo: IO Interactive)
"I'm excited to join IO Interactive, an iconic game studio with a 25-year legacy of maintaining high standards and creating globally recognized franchises. With exciting projects underway and new studios opening across Europe, I look forward to playing a role in IOI's continued growth and success," shared Veronique Lallier.
Veronique brings with her a wealth of experience in the gaming industry with prior roles in leading video game studios such as Hi-Rez Studios, serving as COO and Studio GM; Warner Bros. Interactive Entertainment as Vice President of Digital Publishing; NCSoft as Studio Managing Director but also Rockstar Games and Ubisoft.
“We are glad to welcome Veronique to IOI. She will bring immense experience, having assumed senior roles in household names in the gaming industry both in Eastern and Western studios. Her background in marketing, publishing, and production is a great blend and makes for a unique profile who will be a tremendous asset for our teams as we look to grow and diversify our IPs,” said Hakan Abrak, CEO of IO Interactive.
The team at the newly opened IOI Brighton studio has hit the ground running since last July and is fully integrated into the development process of the projects currently underway at IO Interactive. Adhering to IOI’s philosophy of working on any project from any studio, the Brighton team has already joined working on Project 007, the first James Bond origin story; Project Fantasy, an online fantasy RPG; and HITMAN World of Assassination.
Building upon the core team already in place, IOI’s ambition for its Brighton studio is to expand over the next year and welcome new talent from the exciting UK development scene with 100 positions now open in various roles. IOI is thus carrying on its organic growth which has been building up for the last few years, with the independent developer and publisher looking to bolster its teams.
With now five studios up and running in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton, IOI is gearing up to be in full force to deliver ambitious and innovative new IPs, after the great success brought about by the completion of the HITMAN trilogy.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers
ABOUT IO INTERACTIVE
IO Interactive is an independent videogame developer and publisher with studios in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton. As the creative force behind some of the most talked-about multiplatform video games in the last two decades, IOI is dedicated to creating unforgettable characters and experiences using their award-winning proprietary Glacier technology.
IO Interactive will develop and publish the very first James Bond origin story with the working title Project 007 and is currently developing a new IP under the codename Project Fantasy. For more information, visit https://ioi.dk.
© 2024 IO Interactive A/S. IO Interactive and the IOI logo are registered trademarks of IO Interactive A/S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116212318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom